The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

Regeneron Pharmaceuticals and Sanofi won U.S. Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent for the inflammatory skin condition chronic ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment ...

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at ...

Earendil Labs, an expert in AI-driven research and development of next-generation biologics therapeutics, and Sanofi have ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

Sanofi-Aventis Vietnam Co., Ltd. is seeking to strengthen cooperation with the Ministry of Health (MoH) to increase access to new medicines for Vietnamese people and develop the pharmaceutical ...

Sanofi (Nasdaq: SNY) with We Are ILL, Inc., visits the Nasdaq MarketSite in Times Square. A patient advocacy organization, We Are ILL redefines what “sick” looks like by making the multiple ...

OpenAI has significantly leveled up the image generating capabilities of ChatGPT, as part of an update to the GPT-4o model introduced last May. The new and improved AI image generator is out now ...